Licensing your technology involves developing partnerships. Get to the bottom of what that means to you on Wednesday, May 23, at the Innovacorp Enterprise Centre. Hear from our panel members on the pros and cons of licensing, their experiences in the trenches, and information on licensing options for your technology.

Panel members are:

Vicki Morgan, Director of Business Development, Immunovaccine Inc. (WWW.IMVACCINE.COM) – For more than 15 years, Vicki has been leading business and partnership initiatives across various sized companies, from biotechnology start-ups to Fortune 200 firms. At Immunovaccine, she leads and facilitates the company’s corporate alliances around the globe. She identifies research collaborations and evaluates licensing opportunities for discovery and development of innovative vaccines. Most recently, Vicki worked with several small start-ups in the life sciences sectors, including helping to license technologies and develop corporate strategy at New Perspectives Inc. Prior to New Perspectives, she worked with Nektar Therapeutics, where she was responsible for licensing activities of proprietary products in gastroenterology, pain and oncology therapeutics. Vicki is a member of the Licensing Executives Society and served on the advisory board of Envion International. She received her undergraduate degree in psychology and an MBA from Miami University in Oxford, Ohio.

John MacInnis, President, Ostrea Consulting Inc. – John has over 30 years experience in the pharmaceutical industry, including 15 years in global strategic marketing and business development and two years in private equity. Prior to founding Ostrea Consulting, he was vice president of portfolio development and licensing for Cipher Pharmaceuticals Inc. (Canada). At Cipher, John’s team evaluated several hundred opportunities and supported out-licensing activities for products targeting the US market. Prior to this, John was vice president of new business development for Kromite, a US-based organization supplying out-sourced portfolio management, new product forecasting services and partnering support to pharmaceutical companies. Formerly, he was vice president of business development for DRI Capital’s $150 million private equity royalty fund, and vice president of research. John’s team at DRI assessed numerous potential royalty investments, including inventor, university and company royalty streams. John has a bachelor of commerce from Dalhousie University.

Stewart Hayne, Associate, Cox & Palmer (WWW.COXANDPALMERLAW.COM) – Stewart is an associate lawyer with Cox & Palmer’s Halifax office. His practice focuses on litigation and intellectual property matters. Stewart is a registered Canadian patent agent and a registered Canadian trade-mark agent. His current IP practice includes: IP assignment and licensing transactions; IP development agreements and assisting IP grant applications; patent prosecution and patentability, infringement and freedom to operate opinions; trade-mark prosecution and opposition practice, and infringement and registerability opinions; and domain name arbitration under the CIRA CDRP. Stewart obtained his bachelor of science in physics from St. Francis Xavier University, his master of science in physics from the University of Guelph, and his law degree from Dalhousie University. Stewart practiced IP litigation in Toronto and patent prosecution and IP licensing in Vancouver before returning home and joining the Cox & Palmer team in 2010.

Wednesday, May 23, 2012
9:00 am – 10:00 am (networking and breakfast: 8:30 am – 9:00 am)
Innovacorp Enterprise Centre
1344 Summer Street, Halifax

Please RSVP to Sarah Morris at SMORRIS@INNOVACORP.CA by Tuesday, May 22.